Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / PRTA
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Prothena Corp. Public Ltd. Co. PRTA

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$-244.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company's ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012, and currently trade on The Nasdaq Global Select Market. Our goal is to be a leading biotechnology company focused on the discovery and development of novel therapies to treat diseases caused by protein dysregulation. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery.

Written from the business description in Prothena Corporation plc's annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2024 · Revenue 135.2 · Net income -122.3
100M200M-100M-200M
201120142017202020232025
Compound annual growth
−12.3%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -114.4% · Net -90.5%
-5000%-10000%-15000%
201120182025
ROE
FY2025 · ROE -63.6%
10%20%-20%-40%-60%
201120182025
Three returns, three denominators.
Gross margin·
Operating margin·
Net margin·
EBITDAUSD -213.7M

Each USD of equity lost 64 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 326.8M
EquityUSD 280.5M
CashUSD 307.5M
Current ratio7.72×

Equity funds 86% of total assets.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
PRTA, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B◌0.10.10.10.2◌◌◌0.00.00.00.10.00.0◌
Operating income $B−0.2−0.2−0.2−0.10.1−0.1−0.1−0.2−0.2−0.2−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.2−0.2−0.2−0.10.1−0.1−0.1−0.2−0.2−0.2−0.1−0.0−0.0−0.0−0.0
Income tax $B0.0−0.0−0.0−0.00.0−0.00.0−0.0−0.00.00.00.00.00.00.0
Net income $B−0.2−0.1−0.1−0.10.1−0.1−0.1−0.2−0.2−0.2−0.1−0.0−0.0−0.0−0.0
EPS, diluted $−4.53−2.27−2.76−2.471.38−2.78−1.95−3.93−4.07−4.66−2.66−0.29−2.20−2.84−2.05
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %−63.6−23.3−24.8−21.520.6−48.6−26.1−42.6−39.7−44.1−24.8−3.1−27.4——
Shares out B0.050.050.050.050.050.040.040.040.040.030.030.030.020.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L2
Fiscal year endsDecember 31
Data on record since2011

Share this section

Download image